Multifocal lung cancers - Clonality vs field cancerization and does it matter?

Journal of the National Cancer Institute

Volumn 101, Issue 8, 2009, Pages 541-543

  Gazdar, Adi F ^a,c   Minna, John D ^a,b  

^a Hamon Center for Therapeutic Oncology Research   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RESEARCH; CANCER SCREENING; CLONOGENESIS; COMPUTER ASSISTED TOMOGRAPHY; EDITORIAL; LUNG CANCER; LUNG CARCINOGENESIS; MULTIPLE CANCER; PRIORITY JOURNAL; GENETICS; HUMAN; LUNG TUMOR; NOTE; PATHOLOGY; POINT MUTATION; PROGNOSIS; RISK FACTOR; SECOND CANCER; SMOKING;

DNA; PROTEIN P53; TP53 PROTEIN, HUMAN;

DNA, NEOPLASM; HUMANS; LUNG NEOPLASMS; NEOPLASMS, MULTIPLE PRIMARY; NEOPLASMS, SECOND PRIMARY; POINT MUTATION; PROGNOSIS; RISK FACTORS; SMOKING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 64749109723     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djp059     Document Type: Editorial

References (25)

1. Slaughter DP, Southwick HW, Smejkal W. "Field cancerization" in oral stratifi ed squamous epithelium:clinical implications of multicentric origin. Cancer. 1953;6(5):963-968.
2. Strong MS, Incze J, Vaughan CW. Field cancerization in the aerodigestive tract - its etiology, manifestation, and signifi cance. J Otolaryngol. 1984;13(1):1-6.
3. Wang X, Wang NM, McLennan GT, et al. Evidence for common clonal origin of multifocal lung cancers. J Natl Cancer Inst. 2009;101(8):xxx-xxx.
4. Johnson BE, Cortazar P, Chute JP. Second lung cancers in patients successfully treated for lung cancer. Semin Oncol. 1997;24(4):492-499.
5. Martini N, Melamed MR. Multiple primary lung cancers. J Thorac Cardiovasc Surg. 1975;70(4):606-612.
6. Nakata M, Sawada S, Yamashita M, et al. Surgical treatments for multiple primary adenocarcinoma of the lung. Ann Thorac Surg. 2004;78(4):1194- 1199.
7. Riquet M, Cazes A, Pfeuty K, et al. Multiple lung cancers prognosis:what about histology? Ann Thorac Surg. 2008;86(3):921-926.
8. Rostad H, Strand TE, Naalsund A, Norstein J. Resected synchronous primary malignant lung tumors:a population-based study. Ann Thorac Surg. 2008;85(1):204-209.
9. Trousse D, D'Journo XB, Avaro JP, et al. Multifocal T4 non-small cell lung cancer:a subset with improved prognosis. Eur J Cardiothorac Surg. 2008;33(1):99-103.
10. Yilmaz A, Ertugrul M, Yagci Tuncer L, Sulu E, Damadoglu E. Multiple primary malignancies involving lung:an analysis of 40 cases. Ups J Med Sci. 2008;113(2):193-200.
11. Trousse D, Barlesi F, Loundou A, et al. Synchronous multiple primary lung cancer:an increasing clinical occurrence requiring multidisciplinary management. J Thorac Cardiovasc Surg. 2007;133(5):1193-1200.
12. Flieder DB, Vazquez M, Carter D, et al. Pathologic fi ndings of lung tumors diagnosed on baseline CT screening. Am J Surg Pathol. 2006;30(5):606-613.
13. Wistuba II, Lam S, Behrens C, et al. Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst. 1997;89(18):1366-1373.
14. Wistuba II, Behrens C, Virmani AK, et al. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res. 2000;60(7):1949-1960.
15. Sikkink SK, Liloglou T, Maloney P, Gosney JR, Field JK. In-depth analysis of molecular alterations within normal and tumour tissue from an entire bronchial tree. Int J Oncol. 2003;22(3):589-595.
16. Franklin WA, Gazdar AF, Haney J, et al. Widely dispersed p53 mutation in respiratory epithelium. J Clin Invest. 1997;100(8):2133-2137.
17. Shimizu S, Yatabe Y, Koshikawa T, et al. High frequency of clonally related tumors in cases of multiple synchronous lung cancers as revealed by molecular diagnosis. Clin Cancer Res. 2000;6(10):3994-3999.
18. Jones S, Chen WD, Parmigiani G, et al. Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci USA. 2008;105(11):4283-4288.
19. Udagawa T. Tumor dormancy of primary and secondary cancers. Acta Pathol Microbiol Immunol Scand. 2008;116(7-8):615-628.
20. Naumov GN, Folkman J, Straume O. Tumor dormancy due to failure of angiogenesis:role of the microenvironment. Clin Exp Metastasis. 2009;26(1):51-60.
21. Dacic S, Ionescu DN, Finkelstein S, Yousem SA. Patterns of allelic loss of synchronous adenocarcinomas of the lung. Am J Surg Pathol. 2005;29(7):897-902.
22. Huang J, Behrens C, Wistuba I, Gazdar AF, Jagirdar J. Molecular analysis of synchronous and metachronous tumors of the lung:impact on management and prognosis. Ann Diagn Pathol. 2001;5(6):321-329.
23. Sobin L, Wittekind C. TNM Classifi cation of Malignant Tumours. 6th ed. New York, NY:Wiley-Liss;2002:99-103.
24. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project:proposals for the revision of the TNM stage groupings in the forthcoming(seventh) edition of the TNM Classifi cation of malignant tumours. J Thorac Oncol. 2007;2(8):706-714.
25. Tsunezuka Y, Matsumoto I, Tamura M, et al. The results of therapy for bilateral multiple primary lung cancers:30 years experience in a single centre. Eur J Surg Oncol. 2004;30(7):781-785.